Dr Soliman Abdel Kader Fakeeh (4017)

Currency in SAR
39.54
-0.46(-1.15%)
Closed·
4017 Scorecard
Full Analysis
Trading at a high P/E ratio relative to near-term earnings growth
Earnings results expected in 3 days
4017 is not included in our AI-picked strategies. See which stocks are.
Fair Value
Day's Range
39.3040.02
52 wk Range
37.1072.90
Key Statistics
Bid/Ask
39.52 / 39.54
Prev. Close
40
Open
40
Day's Range
39.3-40.02
52 wk Range
37.1-72.9
Volume
166.04K
Average Volume (3m)
397.31K
1-Year Change
-30.92%
Fair Value
unlockUnlock
Fair Value Upside
unlockUnlock
4017 Scorecardpro icon
Company’s Health
Unlock
Fair Value
Unlock Price
Fair Price
Upside
Price Target
45.28
Upside
+14.53%
Members' Sentiments
Bearish
Bullish
ProTips
Suffers from weak gross profit margins

Technical Analysis

Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Strong Sell

Dr Soliman Abdel Kader Fakeeh Company Profile

Dr. Soliman Abdel Kader Fakeeh Hospital Company, together with its subsidiaries, establishes, operates, and manages hospitals, clinics, medical, educational, and training centers in the Kingdom of Saudi Arabia. It operates through Medical Services; Education; and Trading, Retail & Others segments. The company offers various services, such as assisted reproductive therapy, audiology, bariatric surgery, pediatric, breast feeding, cardiac surgery, cardiology, chest and respiratory diseases, chiropractic medicine, dental and maxillofacial, dermatology, otorhinolaryngology, endocrinology, ophthalmology, family medicine, gastroenterology, general surgery, geriatric medicine, hematology, hyperbaric oxygen service, infectious diseases, internal medicine, interventional radiology, psychiatry, lasik surgery, nephrology, neuro surgery, neurology, nutrition, obstetrics and gynecology, oncology, orthopedics, pediatric orthopedic surgery, pediatric surgery, physical medicine and rehabilitation, plastic surgery, rheumatology, sleep disorders clinic, speech therapy, thoracic surgery, urology, and vascular surgery, as well as pain treatment and palliative care services. It also operates AIRS, anesthesia, burn, diagnostics service, emergency medicine, endoscopy, intensive care, NICU, renal dialysis, rhinoplasty, and institute of robotic surgery facilities; establishes and manages pharmacies; and provides analysis and radiology laboratory, healthcare, medical education, and home health care services. In addition, the company engages in the trading of pharmaceutical products, spectacles, and cosmetics; construction and contracting; wholesale and retail of medical equipment; and maintenance of IT equipment and software related services. The company was incorporated in 1978 and is based in Jeddah, the Kingdom of Saudi Arabia.

Compare 4017 to Peers and Sector

Metrics to compare
4017
Peers
Sector
Relationship
P/E Ratio
28.6x20.7x−0.5x
PEG Ratio
8.750.310.00
Price/Book
3.0x3.1x2.6x
Price / LTM Sales
3.1x3.8x3.2x
Upside (Analyst Target)
12.2%30.2%38.8%
Fair Value Upside
Unlock22.3%5.4%Unlock

Analyst Ratings

0 Buy
4 Hold
2 Sell
Ratings:
6 analysts
Overall Consensus
Neutral

Analysts 12-Month Price Target:

Average 45.28
(+14.53% Upside)

Dividends

Payout Ratio
Payout ratio (TTM)
Earnings retained
EPS 1.40%
Dividend Yield
0.75%
Industry Median 1.76%
Annualised payout
0.30
Paid annually
5-Years Growth
-
Growth Streak

Earnings

Latest Release
May 28, 2025
EPS / Forecast
0.31 / --
Revenue / Forecast
701.00M / --
EPS Revisions
Last 90 days

4017 Income Statement

People Also Watch

60.85
2010
-0.25%
24.95
1150
-0.99%
42.02
7010
+0.05%
12.66
4190
-0.71%
23.80
2222
+0.42%

FAQ

What Stock Exchange Does Dr Soliman Abdel Kader Fakeeh Trade On?

Dr Soliman Abdel Kader Fakeeh is listed and trades on the Saudi Arabia Stock Exchange stock exchange.

What Is the Stock Symbol for Dr Soliman Abdel Kader Fakeeh?

The stock symbol for Dr Soliman Abdel Kader Fakeeh is "4017."

What Is the Dr Soliman Abdel Kader Fakeeh Market Cap?

As of today, Dr Soliman Abdel Kader Fakeeh market cap is 9.20B.

What Is Dr Soliman Abdel Kader Fakeeh's Earnings Per Share (TTM)?

The Dr Soliman Abdel Kader Fakeeh EPS (TTM) is 1.40.

When Is the Next Dr Soliman Abdel Kader Fakeeh Earnings Date?

Dr Soliman Abdel Kader Fakeeh will release its next earnings report on 02 Sept 2025.

From a Technical Analysis Perspective, Is 4017 a Buy or Sell?

Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.

How Many Times Has Dr Soliman Abdel Kader Fakeeh Stock Split?

Dr Soliman Abdel Kader Fakeeh has split 0 times.

How Many Employees Does Dr Soliman Abdel Kader Fakeeh Have?

Dr Soliman Abdel Kader Fakeeh has 2672 employees.

What is the current trading status of Dr Soliman Abdel Kader Fakeeh (4017)?

As of 31 Aug 2025, Dr Soliman Abdel Kader Fakeeh (4017) is trading at a price of 39.54, with a previous close of 40.00. The stock has fluctuated within a day range of 39.30 to 40.02, while its 52-week range spans from 37.10 to 72.90.
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.